Pralidoxime: Difference between revisions
No edit summary |
Bmurray990 (talk | contribs) |
||
| Line 38: | Line 38: | ||
*Half-life: Apparent: 74 to 77 minutes, IM/IV exposure: 3 to 4 hours | *Half-life: Apparent: 74 to 77 minutes, IM/IV exposure: 3 to 4 hours | ||
*Metabolism: Hepatic | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: Urine | ||
*Mechanism of Action: Displaces an organophosphate from acetylcholinesterase (if given early before irreversible enzyme binding occurs, aka "aging") | *Mechanism of Action: Displaces an organophosphate from acetylcholinesterase (if given early before irreversible enzyme binding occurs, aka "aging") | ||
Revision as of 19:02, 26 January 2019
General
- Type:
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Organophosphate toxicity
- 1-2gm IV over 5-10min
- Continuous infusion of 500mg/hr if no initial response
Pediatric Dosing
Organophosphate toxicity
- 20-40mg/kg (up to 1gm) IV over 5-10min
- 5-10mg/kg/hr if no initial response
Special Populations
- Pregnancy Rating:
- Lactation risk:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Tachycardia
- Hypertension
- Laryngospasm
- Hepatitis
Common
Pharmacology
- Half-life: Apparent: 74 to 77 minutes, IM/IV exposure: 3 to 4 hours
- Metabolism: Hepatic
- Excretion: Urine
- Mechanism of Action: Displaces an organophosphate from acetylcholinesterase (if given early before irreversible enzyme binding occurs, aka "aging")